The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Caelyx pegylated liposomal doxorubicin | Baxter Holding B.V. | Sarcoma, Kaposi; Multiple Myeloma; Ovarian Neoplasms; Breast Neoplasms | 🇪🇺 EU 1996-06-20 | Order → |
| Rilutek riluzole | Sanofi Winthrop Industrie | Amyotrophic Lateral Sclerosis | 🇪🇺 EU 1996-06-10 | Order → |
| Zerit stavudine | Bristol-Myers Squibb Pharma EEIG | HIV Infections | 🇪🇺 EU 1996-05-08 | Order → |
| Puregon follitropin beta | Organon N.V. | Infertility; Hypogonadism | 🇪🇺 EU 1996-05-02 | Order → |
| Humalog insulin lispro | Eli Lilly Nederland B.V. | Diabetes Mellitus | 🇪🇺 EU 1996-04-30 | Order → |
| NovoSeven eptacog alfa (activated) | Novo Nordisk A/S | Hemophilia B; Thrombasthenia; Factor VII Deficiency; Hemophilia A | 🇪🇺 EU 1996-02-23 | Order → |
| CellCept mycophenolate mofetil | Roche Registration GmbH | Graft Rejection | 🇪🇺 EU 1996-02-14 | Order → |
| Fareston toremifene | Orion Corporation | Breast Neoplasms | 🇪🇺 EU 1996-02-14 | Order → |
| Betaferon interferon beta-1b | Bayer AG | Multiple Sclerosis | 🇪🇺 EU 1995-11-30 | Order → |
| Taxotere docetaxel | Sanofi Winthrop Industrie | Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Stomach Neoplasms; Breast Neoplasms | 🇪🇺 EU 1995-11-27 | Order → |
| GONAL-f follitropin alfa | Merck Europe B.V. | Anovulation; Reproductive Techniques, Assisted; Infertility, Female; Hypogonadism | 🇪🇺 EU 1995-10-20 | Order → |
| Abilify MyCite aripiprazole | Otsuka Pharmaceutical Netherlands B.V. | Schizophrenia; Bipolar Disorder | 🇪🇺 EU | Order → |
| ABP 710 infliximab | Amgen Europe B.V. | 🇪🇺 EU | Order → | |
| Abylqis arachis hypogaea extract | DBV Technologies | Peanut Hypersensitivity | 🇪🇺 EU | Order → |
| Acrescent memantine hydrochloride;donepezil hydrochloride | H. Lundbeck A/S | Alzheimer Disease | 🇪🇺 EU 2012-10-18 | Order → |
| Adcomfo omalizumab Biosimilar | Advanz Pharma Limited | Asthma; Nasal Polyps; Urticaria | 🇪🇺 EU 2026-09-17 | Order → |
| Adlumiz anamorelin | Helsinn Birex Pharmaceuticals Ltd. | Cachexia; Anorexia; Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2017-09-14 | Order → |
| Aduhelm aducanumab | Biogen Netherlands B.V. | Alzheimer Disease | 🇪🇺 EU | Order → |
| Advexin Orphan | Gendux Molecular Limited | Li-Fraumeni Syndrome | 🇪🇺 EU | Order → |
| Aflunov A/VietNam/1194/2004 | Novartis Vaccines and Diagnostics S.r.l. | Influenza, Human; Immunization; Disease Outbreaks | 🇪🇺 EU | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.